15 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $589M | $214M | 85.2% | 43.8% | $209M | — | $709M |
| 2024 | $492M | $164M | 86.0% | 39.7% | $239M | — | $518M |
| 2023 | $398M | $71M | 86.9% | 21.8% | $143M | — | $138M |
| 2022 | $214M | $83M | 83.9% | 47.5% | $116M | — | $298M |
| 2021 | $141M | $39M | 84.5% | 37.2% | $59M | — | $171M |
| 2020 | $119M | $75M | 85.7% | 34.7% | $45M | — | $130M |
| 2019 | $102M | $32M | 85.6% | 31.1% | $35M | — | $90M |
| 2018 | — | -$34M | — | — | -$26M | — | $17M |
| 2017 | — | -$18M | — | — | — | — | $57M |
| 2016 | — | -$18M | — | — | — | — | $14M |
| 2015 | — | -$20M | — | — | — | — | $28M |
| 2014 | — | -$16M | — | — | — | — | $9M |
| 2014 | — | -$58M | — | — | — | — | $1M |
| 2013 | — | -$12M | — | — | -$10M | — | $2M |
| 2013 | — | -$53M | — | — | -$42M | — | $13M |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $149M | $64M | 90.3% | 49.0% | $60M | — | $756M |
| Dec '25 | $153M | $53M | 82.9% | 40.5% | $45M | — | $709M |
| Sep '25 | $148M | $53M | 84.7% | 44.7% | $32M | — | $690M |
| Jun '25 | $147M | $52M | 85.9% | 45.2% | $71M | — | $653M |
| Mar '25 | $141M | $57M | 87.3% | 44.8% | $60M | — | $581M |
| Dec '24 | $142M | $56M | 84.7% | 44.3% | $71M | — | $518M |
| Sep '24 | $129M | $44M | 85.0% | 39.6% | $73M | — | $442M |
| Jun '24 | $123M | $41M | 87.4% | 44.2% | $64M | — | $376M |
| Mar '24 | $99M | $23M | 87.3% | 27.5% | $32M | — | $310M |
| Dec '23 | $111M | $35M | 85.7% | 37.7% | $56M | — | $138M |
| Sep '23 | $103M | -$31M | 86.2% | -36.2% | $45M | — | $121M |
| Jun '23 | $100M | $38M | 87.9% | 46.9% | $31M | — | $179M |
| Mar '23 | $85M | $30M | 88.3% | 41.7% | $12M | — | $148M |
| Dec '22 | $61M | $25M | 81.6% | 50.7% | $40M | — | $298M |
| Sep '22 | $57M | $23M | 83.1% | 43.9% | $41M | — | $256M |
| Jun '22 | $53M | $22M | 85.6% | 53.8% | — | — | $211M |
| Mar '22 | $43M | $13M | 86.3% | 40.3% | — | — | $178M |
| Dec '21 | $38M | $9M | 80.8% | 33.3% | $19M | — | $171M |
| Sep '21 | $36M | $10M | 85.2% | 38.9% | $22M | — | $155M |
| Jun '21 | $36M | $12M | 87.5% | 43.6% | $16M | — | $135M |
How the market has priced CPRX against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Catalyst Pharmaceuticals, Inc.'s revenue has grown 37.7% per year, and net income grown 23.4% per year. These are computed facts, not advice.
As of FY2025, Catalyst Pharmaceuticals, Inc. reported — of total debt against $709M of cash.
In FY2025, gross margin was 85.2%, operating margin 43.8%, and net margin 36.4%.
As of Jun '26, Catalyst Pharmaceuticals, Inc. traded at a price-to-earnings ratio of about 17.9× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S have moved with the share price. These are computed facts, not advice.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.